Equities analysts expect that Shire (NASDAQ:SHPG) will announce earnings of $3.69 per share for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Shire’s earnings. The lowest EPS estimate is $3.58 and the highest is $3.84. Shire reported earnings per share of $3.73 in the same quarter last year, which indicates a negative year-over-year growth rate of 1.1%. The business is scheduled to announce its next earnings report on Thursday, August 2nd.
According to Zacks, analysts expect that Shire will report full year earnings of $15.26 per share for the current year, with EPS estimates ranging from $15.05 to $15.50. For the next fiscal year, analysts anticipate that the business will post earnings of $16.20 per share, with EPS estimates ranging from $15.08 to $17.50. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Shire.
Shire (NASDAQ:SHPG) last issued its earnings results on Thursday, April 26th. The biopharmaceutical company reported $3.86 EPS for the quarter, topping the consensus estimate of $3.58 by $0.28. The company had revenue of $3.77 billion for the quarter. Shire had a net margin of 28.96% and a return on equity of 13.60%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.63 earnings per share.
SHPG has been the topic of a number of research analyst reports. Royal Bank of Canada set a $186.00 target price on Shire and gave the company a “buy” rating in a report on Sunday, April 22nd. JPMorgan Chase downgraded shares of Shire from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $200.00 to $150.00 in a research report on Monday, February 19th. Zacks Investment Research raised shares of Shire from a “sell” rating to a “hold” rating in a research report on Friday, March 23rd. B. Riley increased their target price on shares of Shire to $200.00 and gave the stock a “buy” rating in a research report on Thursday, April 19th. Finally, ValuEngine downgraded shares of Shire from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. Shire has a consensus rating of “Buy” and an average price target of $201.64.
Shire stock traded up $0.19 during midday trading on Friday, reaching $170.87. The stock had a trading volume of 13,355 shares, compared to its average volume of 1,521,161. Shire has a twelve month low of $169.82 and a twelve month high of $171.04. The stock has a market capitalization of $51.22 billion, a P/E ratio of 11.23, a PEG ratio of 1.33 and a beta of 1.30. The company has a current ratio of 1.14, a quick ratio of 0.66 and a debt-to-equity ratio of 0.45.
The company also recently declared a semiannual dividend, which was paid on Tuesday, April 24th. Shareholders of record on Friday, March 9th were issued a dividend of $0.8937 per share. This represents a yield of 1.33%. This is a boost from Shire’s previous semiannual dividend of $0.15. The ex-dividend date was Thursday, March 8th. Shire’s dividend payout ratio is 6.93%.
Hedge funds have recently added to or reduced their stakes in the business. Boston Partners increased its holdings in Shire by 60.9% during the fourth quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock worth $363,351,000 after buying an additional 886,572 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new position in shares of Shire in the first quarter worth $113,097,000. ING Groep NV increased its position in Shire by 9,043.1% during the 4th quarter. ING Groep NV now owns 524,537 shares of the biopharmaceutical company’s stock valued at $81,366,000 after purchasing an additional 518,800 shares during the period. FNY Partners Fund LP increased its position in Shire by 346.6% during the 4th quarter. FNY Partners Fund LP now owns 474,460 shares of the biopharmaceutical company’s stock valued at $73,598,000 after purchasing an additional 368,214 shares during the period. Finally, First Trust Advisors LP increased its position in Shire by 9.3% during the 4th quarter. First Trust Advisors LP now owns 305,452 shares of the biopharmaceutical company’s stock valued at $47,382,000 after purchasing an additional 26,012 shares during the period. Institutional investors own 18.08% of the company’s stock.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.